176 related articles for article (PubMed ID: 16298826)
21. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Westfall DE; Zhang L; Song S; Lee S
Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
[TBL] [Abstract][Full Text] [Related]
22. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
23. PTHrP-mediated hypercalcaemia in a case of CML blast crisis.
Kubonishi I; Asahi Y; Machida H; Uemura Y; Hatakeyama N; Kubota T; Ohtsuki Y; Miyoshi I
Br J Haematol; 1997 Jan; 96(1):165-7. PubMed ID: 9012703
[TBL] [Abstract][Full Text] [Related]
24. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
25. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
27. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
28. Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Myojo T; Hino N
Intern Med; 2004 Feb; 43(2):126-30. PubMed ID: 15005255
[TBL] [Abstract][Full Text] [Related]
29. Doctors condemn NICE's guidance on leukaemia drug.
Mayor S
BMJ; 2002 Jun; 324(7350):1352. PubMed ID: 12052793
[No Abstract] [Full Text] [Related]
30. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
[No Abstract] [Full Text] [Related]
31. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Moravcová J; Zmeková V; Klamová H; Voglová J; Faber E; Michalová K; Rabasová J; Jarosová M
Leuk Res; 2004 Apr; 28(4):415-9. PubMed ID: 15109543
[TBL] [Abstract][Full Text] [Related]
32. Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Breccia M; Santopietro M; Cannella L; Federico V; Loglisci G; Serrao A; Petrucci L; Salaroli A; Nanni M; De Propris MS; Diverio D; Alimena G
Leuk Res; 2011 Jun; 35(6):e91-2. PubMed ID: 21316103
[No Abstract] [Full Text] [Related]
33. Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.
Alimena G; Breccia M; Mancini M; Diverio D; Nanni M; De Propris MS; Cimino G; Pane F; Mandelli F
Leukemia; 2005 Feb; 19(2):287-9. PubMed ID: 15538403
[No Abstract] [Full Text] [Related]
34. Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Colavita I; Esposito N; Martinelli R; Catanzano F; Melo JV; Pane F; Ruoppolo M; Salvatore F
Biochim Biophys Acta; 2010 Oct; 1804(10):1974-87. PubMed ID: 20417730
[TBL] [Abstract][Full Text] [Related]
35. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
Flamant S; Ritchie W; Guilhot J; Holst J; Bonnet ML; Chomel JC; Guilhot F; Turhan AG; Rasko JE
Haematologica; 2010 Aug; 95(8):1325-33. PubMed ID: 20460641
[TBL] [Abstract][Full Text] [Related]
36. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
[TBL] [Abstract][Full Text] [Related]
37. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
[No Abstract] [Full Text] [Related]
38. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
39. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.
Lange T; Günther C; Köhler T; Krahl R; Musiol S; Leiblein S; Al-Ali HK; van Hoomissen I; Niederwieser D; Deininger MW
Blood; 2003 Mar; 101(6):2152-5. PubMed ID: 12406906
[TBL] [Abstract][Full Text] [Related]
40. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
